A potent and selective ATP-competitive ATR (Ataxia-telangiectasia and Rad3-related protein) inhibitor, Ki=13 nM. Increases the sensitivity of pancreatic and ovarian cancer cells to radiation and chemotherapy. Increased replication stress induced by PARP inhibitors or chemotherapeutic agents increases sensitivity to VE-821 in neuroblastoma cells. Enhances the cytotoxicity of DNA damaging agents.
Application Procedures
First dissolved in DMSO (40 mg/ml), then diluted to aqueous buffer. Solutions in DMSO may be stored at -20°C for up to 1 month.
